- Home
- SITC vs RLMD Comparison
SITC vs RLMD Comparison
Compare SITC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | RLMD |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.6M | 319.0M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | SITC | RLMD |
|---|---|---|
| Price | $6.37 | $3.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.83 | $9.00 |
| AVG Volume (30 Days) | ★ 974.0K | 529.3K |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 107.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $139,962,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $0.24 |
| 52 Week High | $15.29 | $5.12 |
Technical Indicators
Market Signals| Indicator | SITC | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 42.10 |
| Support Level | $5.97 | $3.51 |
| Resistance Level | $6.18 | $3.93 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 97.62 | 33.56 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.